Indication
Age-related macular degeneration
45 clinical trials
49 products
3 drugs
Product
KH631Clinical trial
A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH631 Gene Therapy in Participants With Neovascular Age-related Macular DegenerationStatus: Recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Phase II Trial to Evaluate the Efficacy and Safety of Topical Ocular MG-O-1002 in Patients With Neovascular Age-Related Macular Degeneration (nAMD)Status: Recruiting, Estimated PCD: 2024-03-01
Product
MG-O-1002Clinical trial
A Phase 1 Ascending Dose And Parallel Group Trial To Establish The Safety, Tolerability AND Pharmacokinetic Profile Of Multiple Intravitreous Injections Of ARC1905 (ANTI-C5 APTAMER) Given Either In Combination Therapy With Multiple Doses Of Lucentis® 0.5 mg/Eye, Or With One Induction Dose Of Lucentis® 0.5 mg/Eye In Subjects With Neovascular Age-Related Macular DegenerationStatus: Completed, Estimated PCD: 2011-03-01
Product
ARC1905Product
Fovista®Product
ranibizumabProduct
BBC1501Clinical trial
A Phase 1, Open Label, Ascending Dose Study to Evaluate the Safety of BBC1501 Administered by Intravitreal Injection for Neovascular Age-Related Macular Degeneration (nAMD)Status: Not yet recruiting, Estimated PCD: 2024-05-01
Product
bevacizumabProduct
afliberceptProduct
ALK-001Clinical trial
A Phase 2/3 Multicenter, Randomized, Double-masked, Parallel-group, Placebo-controlled Study to Investigate the Safety, Pharmacokinetics, Tolerability, and Efficacy of ALK-001 in Geographic Atrophy Secondary to Age-related Macular DegenerationStatus: Active (not recruiting), Estimated PCD: 2023-07-25
Product
PlaceboProduct
E10030 plus LucentisClinical trial
A Phase 2, Randomized, Double-Masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Injections of E10030 (Anti-PDGF Pegylated Aptamer) Given in Combination With Lucentis in Subjects With Neovascular Age-Related Macular DegenerationStatus: Completed, Estimated PCD: 2012-06-01
Product
LucentisClinical trial
A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista® (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration.Status: Terminated, Estimated PCD: 2017-06-01
Product
E10030Clinical trial
A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista® (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration.Status: Terminated, Estimated PCD: 2016-12-01
Clinical trial
Screening And Detecting Eye Diseases With Hybrid Deep Learning Algorithms From Fundus Images And Validation Of Automated Artificial Intelligence AlgorithmStatus: Recruiting, Estimated PCD: 2024-03-01
Product
Mydriatic AgentClinical trial
A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Intravitreous Administration of Fovista® (Anti PDGF-B Pegylated Aptamer) Administered in Combination With Lucentis® Compared to Lucentis® Monotherapy in Subjects With Subfoveal Neovascular Age-related Macular Degeneration.Status: Terminated, Estimated PCD: 2016-12-01
Product
BevacizumabClinical trial
A Phase 1/2a Open-label Study to Evaluate Safety, Tolerability and Preliminary Efficacy of NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular DegenerationStatus: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
ReNEW: A Phase 3, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)Status: Not yet recruiting, Estimated PCD: 2026-08-01
Product
ElamipretideProduct
NG101Product
VOY-101Clinical trial
Phase 1/2a Dose Escalation Study of VOY-101 in Patients With Advanced Non- Neovascular Age-Related Macular DegenerationStatus: Recruiting, Estimated PCD: 2026-10-01
Product
E10030 + LucentisClinical trial
A Phase I Study of ARC1905 (Anti-C5 Aptamer) in Subjects With Dry Age-related Macular DegenerationStatus: Completed, Estimated PCD: 2012-11-01
Product
Eyecyte-RPE™Clinical trial
A Phase 1/2a Multi-Center, Dose-Escalation Study to Evaluate the Safety & Efficacy of Eyecyte-RPE™ When Administered as a Single-dose Subretinal Injection in Subjects With Geographic Atrophy Secondary to Dry Age-related Macular DegenerationStatus: Not yet recruiting, Estimated PCD: 2024-10-01
Clinical trial
An Open-label Extension (OLE) Phase 3 Trial to Assess the Safety of Intravitreal Administration of Avacincaptad Pegol (Complement C5 Inhibitor) in Patients With Geographic Atrophy Who Previously Completed Phase 3 Study ISEE2008 (GATHER2)Status: Active (not recruiting), Estimated PCD: 2025-03-31
Clinical trial
A Randomized, Participant and Investigator Masked, Placebo-controlled, Multicenter, Proof-of-concept Study to Assess the Safety and Efficacy of LNP023 (Iptacopan) in Patients With Early and Intermediate Age-related Macular DegenerationStatus: Recruiting, Estimated PCD: 2026-11-25
Product
IptacopanClinical trial
A Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).Status: Recruiting, Estimated PCD: 2027-07-15
Product
Placebo ComparatorProduct
CT1812Product
AvacincaptadClinical trial
A Randomized, Partially Masked, Controlled, Phase 2b/3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMD (ATMOSPHERE)Status: Recruiting, Estimated PCD: 2025-05-01
Product
RGX-314Product
RanibizumabProduct
bevacizumab or afliberceptProduct
OpRegenClinical trial
Phase I/IIa Dose Escalation Safety and Efficacy Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelium Cells Transplanted Subretinally in Patients With Advanced Dry-Form Age-Related Macular Degeneration (Geographic Atrophy)Status: Active (not recruiting), Estimated PCD: 2021-12-31
Clinical trial
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus PFS in Subjects With Visual Impairment Due to Retinal Disorders, NORSE SEVENStatus: Active (not recruiting), Estimated PCD: 2025-03-01
Product
RetinoStatClinical trial
A Long Term Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular DegenerationStatus: Active (not recruiting), Estimated PCD: 2029-03-01
Clinical trial
A Phase III, Multicenter, Randomized, Two-armed, Double-blind, Parallel, Active-controlled, Non-inferiority Clinical Trial to Compare Efficacy and Safety of Aflibercept (CinnaGen Co, Iran) to the Reference Aflibercept Product (Eylea®, Regeneron, USA) in Patients With Neovascular Age-related Macular Degeneration.Status: Completed, Estimated PCD: 2022-07-31
Clinical trial
A Multicenter, Randomized, Double-masked Phase 3a Study to Assess Safety and Efficacy of Brolucizumab 6 mg q4 Weeks Compared to Aflibercept 2 mg q4 Weeks in Patients With Neovascular Age-related Macular Degeneration (nAMD) With Persistent Retinal Fluid (MERLIN)Status: Terminated, Estimated PCD: 2020-12-21
Product
AfliberceptProduct
BrolucizumabClinical trial
A Phase I/II, Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of KH631 Gene Therapy in Subjects With Neovascular Age-related Macular Degeneration (nAMD)Status: Recruiting, Estimated PCD: 2026-12-28
Product
SF0166Clinical trial
A Phase I/II Randomized, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of SF0166 Topical Ophthalmic Solution in the Treatment of Neovascular Age-Related Macular Degeneration (AMD)Status: Completed, Estimated PCD: 2017-06-26
Clinical trial
A Randomized, Partially Masked, Controlled, Phase 3 Clinical Study to Evaluate the Efficacy and Safety of RGX-314 Gene Therapy in Participants With nAMDStatus: Recruiting, Estimated PCD: 2025-02-01
Clinical trial
A Double-Masked, Multi-center, Active Controlled Safety and Efficacy Study of Adjunct Episcleral Brachytherapy for Polypoid Choroidal VasculopathyStatus: Not yet recruiting, Estimated PCD: 2026-09-01
Clinical trial
A Multicenter Real-life Observational Retrospective Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With Refractory or Dependent Exudative AMDStatus: Not yet recruiting, Estimated PCD: 2025-04-01
Product
FaricimabClinical trial
The Role of Loteprednol in Reducing Post-Intravitreal Injection Related PainStatus: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
Tolerating Subretinal Fluid in Type 1 Macular Neovascularization and Polypoidal Choroidal Vasculopathy Treated Using AfliberceptStatus: Completed, Estimated PCD: 2023-05-31
Product
Intravitreal afliberceptClinical trial
The Effects of Disulfiram on Visual Acuity in Patients With Retinal DegenerationStatus: Not yet recruiting, Estimated PCD: 2025-04-15
Product
DisulfiramClinical trial
An Investigation of Vitamin A Palmitate Supplementation in Patients With Age-Related Macular Degeneration (and Without Reticular Pseudodrusen) and Delayed Dark AdaptationStatus: Active (not recruiting), Estimated PCD: 2023-06-16
Product
Vitamin A palmitateClinical trial
Adherence to Lifestyle Changes for Age-related Macular DegenerationStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Product
Risk profilingClinical trial
Optical Coherence Tomography Angiography and Microperimetry After Aflibercept in Wet Age-related Macular Degeneration Patients With the Better Baseline Visual Acuity (≥20/40)Status: Completed, Estimated PCD: 2022-02-28
Clinical trial
A Phase 1b, Multicenter, Dose Escalation, Evaluation of Safety and Tolerability of ASP7317 for Geographic Atrophy Secondary to Age-related Macular DegenerationStatus: Recruiting, Estimated PCD: 2026-01-31
Product
ASP7317Drug
tacrolimusProduct
AcyclovirProduct
NystatinClinical trial
An Investigation of Vitamin A Palmitate Supplementation in Patients With Reticular Pseudodrusen (RPD) and Delayed Dark AdaptationStatus: Active (not recruiting), Estimated PCD: 2022-06-17
Product
Vitamin A PalmitateClinical trial
METforMIN: Metformin Administration for the Minimization of Geographic Atrophy Progression in Patients With Age-related Macular DegenerationStatus: Completed, Estimated PCD: 2022-04-01
Drug
MetforminClinical trial
: Effect of Supplementation With Lutein, Zeaxanthin and Saffron on the Intestinal Microbiota in Patients Suffering From Age-related Macular Degeneration - The Gut-Retina-axis Study"Status: Active (not recruiting), Estimated PCD: 2022-03-01
Product
anti-VEGFClinical trial
Evaluation of Oral Minocycline in the Treatment of Geographic Atrophy Associated With Age-Related Macular DegenerationStatus: Completed, Estimated PCD: 2022-09-28
Product
MinocyclineClinical trial
Targeted Fluorescence Imaging Using Bevacizumab-800CW Within Age-related Macular Degeneration (AMD) Patients to Evaluate the Upregulation of VEGFStatus: Recruiting, Estimated PCD: 2023-09-30
Product
Bevacizumab-IRDye800CWProduct
Vedolizumab-IRDye800CWClinical trial
A Non-Randomized, Open Label, Safety and Efficacy Study Evaluating Kamuvudine-8 (K8) for the Treatment of Patients With Geographic AtrophyStatus: Recruiting, Estimated PCD: 2024-12-01
Product
K8Clinical trial
Safety and Effectiveness of ONS-5010 Compared to Lucentis® in Subjects With Neovascular Age-related Macular Degeneration; NORSE EIGHTStatus: Recruiting, Estimated PCD: 2024-09-01
Drug
bevacizumabClinical trial
Treatment of Recalcitrant Neovascular AMD Using Brolocizumab With a Novel Treat and Extend Protocol - a Randomized Controlled Prospective StudyStatus: Completed, Estimated PCD: 2023-07-25